Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIBRANT: verekitug in chronic rhinosinusitis with nasal polyps
2023-508231-31-00Phase 2Completed
- Sponsor
- Upstream Bio
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial in chronic rhinosinusitis with nasal polyps (CRSwNP) comparing Verekitug + background nasal corticosteroid with Placebo + background nasal corticosteroid (2 arms). Primary endpoint: Change from baseline at Week 24 in nasal polyp score. Started Apr 2024; status: completed.
02
Drugs
vereckitug
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on 2023-508231-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508231-31-00.